Sangamo Therapeutics, Inc. (NASDAQ:SGMO)‘s stock had its “buy” rating reissued by Jefferies Group LLC in a report released on Thursday. They presently have a $18.00 price objective on the biopharmaceutical company’s stock. Jefferies Group LLC’s target price suggests a potential upside of 29.45% from the company’s previous close.

A number of other equities research analysts have also recently commented on SGMO. ValuEngine raised Sangamo Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. Zacks Investment Research cut Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. BidaskClub cut Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, July 28th. Piper Jaffray Companies set a $8.00 target price on Sangamo Therapeutics and gave the stock a “hold” rating in a research note on Thursday, August 10th. Finally, Wells Fargo & Company reissued an “outperform” rating and issued a $30.00 target price (up from $20.00) on shares of Sangamo Therapeutics in a research note on Tuesday, September 5th. One analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $14.40.

Shares of Sangamo Therapeutics (SGMO) traded up 3.77% during trading on Thursday, reaching $13.90. The company’s stock had a trading volume of 1,677,161 shares. The stock’s 50 day moving average is $10.71 and its 200 day moving average is $7.45. The firm’s market cap is $1.16 billion. Sangamo Therapeutics has a one year low of $2.65 and a one year high of $15.05.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.06. Sangamo Therapeutics had a negative return on equity of 38.49% and a negative net margin of 246.39%. The company had revenue of $8.30 million for the quarter, compared to analysts’ expectations of $5.82 million. During the same period in the prior year, the firm earned ($0.38) earnings per share. The firm’s revenue for the quarter was up 124.3% on a year-over-year basis. On average, equities analysts forecast that Sangamo Therapeutics will post ($0.82) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Sangamo Therapeutics, Inc. (SGMO) Receives “Buy” Rating from Jefferies Group LLC” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/09/14/sangamo-therapeutics-inc-sgmo-receives-buy-rating-from-jefferies-group-llc.html.

In related news, VP Curt A. Herberts III sold 15,000 shares of the stock in a transaction on Friday, July 14th. The stock was sold at an average price of $10.00, for a total transaction of $150,000.00. Following the sale, the vice president now directly owns 35,517 shares of the company’s stock, valued at $355,170. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, VP Curt A. Herberts III sold 11,474 shares of the stock in a transaction on Monday, August 14th. The shares were sold at an average price of $10.44, for a total value of $119,788.56. Following the sale, the vice president now directly owns 23,991 shares in the company, valued at $250,466.04. The disclosure for this sale can be found here. Insiders have sold 41,474 shares of company stock worth $494,789 over the last ninety days. 8.10% of the stock is currently owned by insiders.

Institutional investors have recently added to or reduced their stakes in the stock. Blair William & Co. IL boosted its position in shares of Sangamo Therapeutics by 4.3% during the second quarter. Blair William & Co. IL now owns 12,100 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 500 shares during the last quarter. Aperio Group LLC purchased a new stake in shares of Sangamo Therapeutics during the second quarter valued at $108,000. Principal Financial Group Inc. boosted its position in shares of Sangamo Therapeutics by 6.8% during the second quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 832 shares during the last quarter. Virtu KCG Holdings LLC purchased a new stake in shares of Sangamo Therapeutics during the second quarter valued at $124,000. Finally, Fox Run Management L.L.C. purchased a new stake in shares of Sangamo Therapeutics during the second quarter valued at $126,000. 63.43% of the stock is currently owned by institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Analyst Recommendations for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.